In this review, we aim to describe racial differences in response to treatment for metastatic castration-resistant prostate cancer (mCRPC).
Recent data suggests that, despite higher risk features, African Americans may respond better than Caucasians to systemic therapies for advanced prostate cancer.
This improved response is not limited to one class of drugs but can be seen with androgen-pathway directed therapies, chemotherapy, bone-targeted therapy, and immunotherapy. The mechanisms for this are being further explored. African Americans may respond better to mCRPC treatments but validation in prospective clinical trials is needed.
Current oncology reports. 2020 Jul 23*** epublish ***
Rhonda L Bitting, Michael Goodman, Daniel J George
Durham VA Health Care System, Durham, NC, USA. ., Comprehensive Cancer Center of Wake Forest University, Winston Salem, NC, USA., Duke Cancer Institute, Center for Prostate & Urologic Cancers, Duke University, Duke Box 103861, Durham, NC, 27710, USA.
Go Beyond the Abstract and Read a Commentary by the Author